Medindia
Medindia LOGIN REGISTER
Advertisement

Vibativ's Delayed Approval for Nosocomial Pneumonia Will Significantly Reduce Its Commercial Impact in the Methicillin-Resistant Staphylococcus Aureus Drug Market

Thursday, February 18, 2010 General News
Advertisement
In 2018, Vibativ Will Garner Less Than Half of What it Had Been Previously Forecasted to Earn, According to New Findings from Decision Resources

For more information, contact:

Decision Resources

Decision Resources, Inc.

Gisselle Morales

Christopher Comfort

781-296-2691

781-296-2597

[email protected]

[email protected]

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close